Evidence map›Paper›PMID 32138474›Full record

ArticleKidney research and clinical practice2020

Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement.

Kyu Yeon Hur, Mee Kyoung Kim, Seung Hyun Ko, Miyeun Han, Dong Won Lee, Hyuk-Sang Kwon, Committee of Clinical Practice Guidelines, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Society of Nephrology

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney research and clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Review
  7. KRCP's past and future path.Kidney research and clinical practice · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Kyu Yeon HurDivision of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-3065-7252
Mee Kyoung KimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-3205-9114
Seung Hyun KoDivision of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea.ORCID https://orcid.org/0000-0003-3703-1479
Miyeun HanDivision of Nephrology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea.ORCID https://orcid.org/0000-0001-7304-2496
Dong Won LeeDivision of Nephrology, Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea.ORCID https://orcid.org/0000-0003-0282-484X
Hyuk-Sang KwonDivision of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-4026-4572
Committee of Clinical Practice Guidelines
Korean Diabetes Association and Committee of the Cooperative Studies
Korean Society of Nephrology
The Catholic University of Korea Yeouido St. Mary's Hospital · KRPusan National University · KRPusan National University Hospital · KRSamsung Medical Center · KRThe Catholic University of Korea St. Vincent's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The safety of metformin use for patients with type 2 diabetes mellitus (T2DM) and advanced kidney disease is controversial, and more recent guidelines have suggested that metformin be used cautiously in this group until more definitive evidence concerning its safety is available. The Korean Diabetes Association and the Korean Society of Nephrology have agreed on consensus statements concerning metformin use for patients with T2DM and renal dysfunction, particularly when these patients undergo imaging studies using iodinated contrast media (ICM). Metformin can be used safely when the estimated glomerular filtration rate (eGFR) is ≥ 45 mL/min/1.73 m

Indexed as

Contrast mediaDiabetes mellitusMetforminRenal insufficiency

Identifiers

PMID32138474
PMCPMC7105629
OpenAlexW3010405652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.